CD19 and neoplasm: As observed in a previous study based on iC9 to lower CAR-T activity [16], animals were resistant to subsequent tumor challenge compared with naive mice, presumably due to residual T cells expressing reduced levels of iC9-CD19.ζ-MC (Fig. 3e, f).